

Tentative Outline

Special Thematic Issue for Current Medicinal Chemistry

Kinase Inhibitors In Drug Discovery

Guest Editor: Dr. Vikas Sharma

- **Aims & Scope:**

Protein kinase is among largest protein families and having important role in cell signaling. The 518 protein kinases encoded in the human genome are regulating different cellular processes. Around 25 kinase inhibitors have been approved till date while many are under clinical trials. Thus by regulating protein kinase number of potential therapeutic agents could be designed against different ailments. Due to its importance, kinase inhibitors are involved in treatment of number of diseases like neurodegenerative disorders, cardiovascular diseases, cancer etc. This thematic issue will cover expose the versatility of protein kinase as drug target.

Keywords: Protein Kinase, inhibitors, cancer, diabetes, neurodegenerative disorder.

Sub-topics:

The sub-topics to be covered within the issue should be provided:

1. Kinase inhibitors in cancer drug designing
2. Kinase inhibitors: *in silico* drug designing
3. Kinase inhibitors in antiviral therapy.
4. Kinase inhibitors in Alzheimer's disease.
5. Kinase inhibitors in anti diabetic therapy.
6. Kinase inhibitors in neurodegenerative disorders.
7. Kinase inhibitors in cardiovascular diseases.

Tentative titles of the articles and list of contributors:

Dr. Pradeep Kumar

Pharmaceutics, Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburg, South Africa.

Email: pradeep.kumar@wits.ac.za

Title: "Can nanomedicinal approaches provide an edge to the efficacy of tyrosine kinase inhibitors?"

Dr. Kamal Dua

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.

Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.

Email: Kamal.Dua@uts.edu.au

Title: "Recent Trends in rationally designed molecules as kinase inhibitors".

Prof. Patrick T. Flaherty

Division of Medicinal Chemistry, School of Pharmacy, Duquesne University, 410A Mellon Hall, 600 Forbes Avenue, Pittsburgh, PA 15282, United States

Email: flahertyp@duq.edu

Title: "MEK5 inhibitors".

Prof. Vikas Sharma

Lovely School of Pharmaceutical Sciences, Lovely Professional University,

Phagwara, Punjab-144411, India Email: vikaspharma26@gmail.com

Title: "Anticancer effects of heterocyclic derivatives as kinase hinge binders."

Schedule:

✧ Thematic issue submission deadline: 30th September 2021

Contacts:

Guest Editor Name: Dr. Vikas Sharma

Affiliation: Lovely School of Pharmaceutical Sciences,

Lovely Professional University,

Phagwara, Punjab-144411, India.

Email: vikaspharma26@gmail.com